Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report

29Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

AZD9291, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), benefits patients with T790M mutant non-small-cell lung cancer who fail treatment with first-generation EGFR TKIs. Acquisition of resistance to AZD9291 occurs inevitable and mechanisms need to be explored. We reported an advanced lung adenocarcinoma female with EGFR exon19 deletion treated on AZD9291 after failure of erlotinib and chemotherapy. Disease progressed again after 6 months' treatment of AZD9291 with hepatic metastasis. Re-biopsy of the hepatic lesion showed histopathology transformation to small cell lung cancer, which harbored EGFR exon19 deletion. Therefore, small cell carcinoma transformation is one of potential resistance mechanisms to AZD9291 and regimen for small cell carcinoma may be one of the treatment options.

Cite

CITATION STYLE

APA

Li, L., Wang, H., Li, C., Wang, Z., Zhang, P., & Yan, X. (2017). Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report. Oncotarget, 8(11), 18609–18614. https://doi.org/10.18632/oncotarget.14506

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free